Stocks
Braveheart Bio, Inc.BRVE
NASDAQHealthcareBiotechnology$19.21
Price as of · delayed, not real-time
A clinical-stage biopharmaceutical company developing treatments for central nervous system disorders, with a focus on rare and orphan indications. Its pipeline includes novel small molecules targeting neurodegenerative diseases, and investor attention centers on upcoming clinical trial readouts that could validate the platform.
52W Range: $17.86-$32.00
Congressional Interest in Braveheart Bio, Inc. (BRVE)
No congressional trades have been disclosed for Braveheart Bio, Inc. (BRVE) yet. All data is sourced from STOCK Act periodic transaction reports filed with Congress.
Total Disclosures
0
Unique Politicians
0
Buys
0
Sells
0
Who in Congress Is Trading BRVE?
No congressional trades found for this stock.